- FDA approves Merck's ragweed allergy remedy Ragwitek
- NACDS RxImpact shines spotlight on pharmacists' increasing role in delivery of healthcare services
- FDA considering two new allergy remedies
- NACDS supports bill to curb Rx abuse, safeguard patients
- Insurance rollout shows pharmacies and NACDS in action
WHITEHOUSE STATION, N.J. — Drug maker Merck is seeking regulatory approval for an experimental tablet placed under the tongue that could be used to treat ragweed allergies.
Merck said the Food and Drug Administration accepted a regulatory application for its ragweed pollen sublingual allergy immunotherapy tablet. Ragweed, also known as Ambrosia artemisiifolia, is a major cause of seasonal allergies in the United States. Merck also submitted an application for a similar drug, for Timothy grass pollen allergies, in March.
The company expects the FDA to complete its review of both applications in the first half of next year. The drugs work by dissolving under the tongue and treating the underlying cause of allergic rhinitis by generating an immune response.